Search clinical trials for: Secukinumab 150mg s.c.

Total 3163 results

Tongji Hospital
Wuhan Central Hospital; Wuhan Hospital of Traditional Chinese Medicine

Recruiting

A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis

Ankylosing Spondylitis (AS)

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of SYHA1402 in Healthy Subjects

Diabetic Peripheral Neuropathy
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis (STATURE)

Plaque-type Psoriasis

United States, Austria, Germany, France, Japan, Canada, Slovakia, India
Stealth BioTherapeutics Inc.

Completed

A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)

Healthy

United States
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

A Randomized, Double-blind,Dose-escalating, Single-dose, Oral Phase I Clinical Study of Flunotinib Healthy People

Healthy Person

China
YD Global Life Science Co., Ltd.

Unknown

The Study to YD312 Tablet in Patients With Diabetic Macular Edema

Diabetic Macular Edema(DME)

United States, Korea, Republic of
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Plaque Psoriasis

China, Thailand, Philippines, Turkey, Hungary, Malaysia
Chengdu Zenitar Biomedical Technology Co., Ltd

Not yet recruiting

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors

Myeloproliferative Neoplasm (MPN) | Myelofibrosis，MF
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Safety of Flunotinib Maleate Tablets for the Treatment of Patients With Myeloproliferative

Myeloproliferative Neoplasm (MPN) | Myelofibrosis，MF

China
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission (GigAINt)

Giant Cell Arteritis

Germany
Pfizer

Completed

Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy Participants

Inflammatory Bowel Disease

China
Novartis Pharmaceuticals

Recruiting

Secukinumab Open Label Roll-over Extension Protocol

Autoimmunity, Inflammation

China, United States, Spain, Czechia, Mexico, Bulgaria, Colombia, Brazil, Russian Federation, Guatemala, South Africa, India, Malaysia, Korea, Republic of, Poland, Greece
Novartis Pharmaceuticals

Completed

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) (JUNCTURE)

Plaque-type Psoriasis

Germany, United States, France, Estonia, Canada
Novartis Pharmaceuticals

Completed

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis (MEASURE4)

Spondylitis, Ankylosing

Germany, Austria, Denmark, United States, Australia, Netherlands, Poland, Italy, Bulgaria, Spain, Russian Federation, United Kingdom, Greece, Czechia, Canada, Norway, Slovakia, Switzerland, Finland
Abivax S.A.

Completed

A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults

HIV Infections | Health Volunteers

Spain
The Affiliated Hospital of Qingdao University

Completed

A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers

Healthy Volunteers

China
Novartis Pharmaceuticals

Completed

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

Psoriatic Arthritis

United States, Puerto Rico
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE)

Moderate to Severe Plaque-type Psoriasis

United States, Czech Republic, Austria, Germany, India, Japan, Bulgaria, Singapore, Switzerland, United Kingdom, Italy, France, Poland, Slovakia, Canada, Vietnam
Inmagene LLC

Completed

Study to Evaluate IMG-004 in Healthy Participants

Healthy Participants

United States
Novartis Pharmaceuticals

Completed

Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis (ASTRUM)

Ankylosing Spondylitis

Germany
GlaxoSmithKline

Withdrawn

GSK2190915 Pediatric Study

Asthma
MyMD Pharmaceuticals, Inc.

Completed

Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty

Frailty | Sarcopenia | Aging

United States
Novartis Pharmaceuticals

Completed

Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab

Palmoplantar Pustular Psoriasis

Germany, Belgium, Austria, Italy, Spain, France, Sweden, United Kingdom, Russian Federation, Poland
West China Hospital

Recruiting

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

Esophageal Squamous Cell Carcinoma

China
West China Hospital

Recruiting

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Esophageal or Head and Neck Squamous Cell Carcinomas

Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Samsung Medical Center
Dong-A Pharmaceutical Co., Ltd.

Unknown

Zydena on Cognitive Function of Alzheimer's Disease Patients

Alzheimer's Disease

Korea, Republic of
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
LG Chem

Completed

An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)

Type 2 Diabetes Mellitus

China
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Study of Tolerability, Safety, and Pharmacokinetics of ZL-82 in Healthy Adult Subjects.

Rheumatoid Arthritis (RA) | Inflammatory Bowel Disease - IBD1

China
Singapore General Hospital
Duke-NUS Graduate Medical School; 60 Degrees Pharmaceuticals LLC

Withdrawn

Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore

Dengue Fever

Singapore
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People

Diabetic Neuropathy Peripheral

China
HK inno.N Corporation
Asan Medical Center

Completed

To Investigate Pharmacokinetics and Pharmacodynamics of CJ-12420 After Single and Multiple Dose Administration

Healthy
Klinikum Nürnberg

Recruiting

A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease. (DapaBalci-Leap)

Chronic Renal Failure | Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis

Germany, France
Sprout Pharmaceuticals, Inc

Completed

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

Sexual Dysfunctions, Psychological

United States, Canada
JW Pharmaceutical

Completed

Therapeutic Exploratory Study of CWP-0403

Type 2 Diabetes Mellitus

Korea, Republic of
Instituto de Investigacion Sanitaria La Fe

Completed

Observational Retrospective Study of Effectivity and Tolerability in Patients With Lacosamide Medication

Epilepsy

Spain
Guangdong Raynovent Biotech Co., Ltd

Completed

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the Effect of Food on ZSP0678 Pharmacokinetics

Nonalcoholic Steatohepatitis

China
Novartis Pharmaceuticals

Completed

Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia

Schizophrenia Disorders

United States
Landos Biopharma Inc.

Recruiting

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Belgium, Italy, Poland
Stealth BioTherapeutics Inc.

Completed

Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days

Healthy Volunteers

United States
BeBetter Med Inc

Completed

Study of Orally Administered BEBT-503 in Healthy Subjects

Healthy Subjects

Australia
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

Hypertension

China
Huabo Biopharm Co., Ltd.

Completed

A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Edesa Biotech Inc.
JSS Medical Research Inc.

Recruiting

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19

COVID-19 | ARDS

United States, Canada
Shandong Luoxin Pharmaceutical Group Stock Co.,...

Completed

A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability.

Healthy

China
HK inno.N Corporation

Completed

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease

Non-erosive Reflux Disease

Korea, Republic of
CSPC Ouyi Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects

Healthy Participants

China
Zambon SpA

Withdrawn

Safinamide for Levodopa-induced Dyskinesia (PD-LID)

Parkinson Disease | Dyskinesia, Drug-Induced
Bacainn Therapeutics, Inc.

Completed

A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

Healthy Volunteers

United States
Dong-A ST Co., Ltd.

Active, not recruiting

Phase 1 Clinical Trial to Evaluate the Safety, PK and PD of DA-5207 TDS in Healthy Adults

Healthy

Korea, Republic of

3

Subscribe